COVID-19 Vaccine Updates: Another important step has been overcome regarding the Coronavirus prevention vaccine. The Serum Institute of India (SII) and the Indian Council of Medical Research (ICMR) have announced that the nomination process for Phase III clinical trial of COVISHIELD has been completed in the country. Enrollment of 1600 people has been done for this phase. The nomination process was completed by 31 October.
SII and ICMR are working together for clinical trials of vaccines in the country. ICMR is funding for the clinical trial site Fei. At the same time, SII is bearing other expenses regarding Kovishield. According to the SII statement, it will have a trial at 15 places across the country. The second phase of the trial was also held at 15 places.
SII has prepared 4 crore doses
SII has already prepared 4 crore doses under the At-Risk Manufacturing and Stockpiling License from Drugs Controller. Kovishield has been prepared at SII’s laboratory in Pune. This vaccine has been developed by Astra Zeneca and Oxford University, which is being further developed at SII’s laboratory in Pune.
SII is also working on another vaccine
Apart from Kovyshield, ICMR and SII are also working together for another vaccine Kovovax. Kovovax has been developed by the American company Novavax, which is being developed by SII.
90% successful vaccine test for the first time in the world
Trials are underway worldwide for the vaccine. A few days ago Pfizer Inc. said that the vaccine trial has been very successful. According to the company’s claim, the vaccine developed by it for prevention of corona virus is proving to be more than 90 percent effective.
It is a major success in the fight against the coronavirus, which has not only ended the lives of many people but has also affected the economies around the world. Let us tell you that Pfizer Inc. and its partner BioNotech SE is the first company in the world to have success in the trial of Corona vaccine on a large scale.